drugset / Trial / NCT07686263

Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

NCT07686263

Phase 3 Not yet recruiting 472 enrolled Karuna Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

Timeline

Start
2026-09-03
Primary completion
2029-03-03
Completion
2029-03-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Trospium Small molecule
Subject Xanomeline Small molecule

Indications